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Interleukin 18 (IL-18) is a pro-inflammatory cytokine, which has been shown to be implicated in
the induction of airway hyperresponsiveness (AHR) in murine asthma models. The association
of IL-18 with AHR in human bronchial asthma is not clear as yet. As cigarette smoking modifies
airway inflammation we aimed to assess the relationship of IL-18 with airway hyperresponsive-
ness (AHR) in non-smoking versus smoking asthmatics.
IL-18 was measured in sputum supernatants obtained from asthmatic (24 smokers and
22 non-smokers) and healthy subjects (16 smokers and 17 non-smokers). All subjects were as-
sessed by spirometry, skin-prick tests to common aeroallergens and bronchial provocation to
methacholine (Mch).
There was no significant difference in IL-18 levels between healthy and asthmatic smokers
and between healthy and asthmatic non-smokers. IL-18 levels in sputum were significantly
lower in healthy smokers compared to non-smokers (pZ 0.048); similarly, in asthmatic
smokers as compared to non-smokers (pZ 0.037). An inverse correlation was found between
IL-18 levels, FEV1 (% pred) (rZ0.495, pZ 0.043), and PD20Mch in non-smoking asthmatics
(rZ 0.621, pZ 0.024). A positive correlation was found in smoking asthmatics between
IL-18 levels in sputum and FEV1 (% pred) (rZ 0.627, pZ 0.002), FVC (% pred) (rZ 0.460,
pZ 0.031), and PD20Mch (rZ 0.809, pZ 0.005).ent of Respiratory Medicine, University of Athens, Medical School, ‘‘Sotiria’’ Hospital for Diseases of
GR-11527, Greece. Tel.: þ30 210 7763314; fax: þ30 210 7239127.
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1920 N. Rovina et al.Cigarette smoking reduced IL-18 levels in induced sputum in healthy and asthmatic smokers.
IL-18 levels were correlated with airway obstruction and AHR in an inverse way in smoking and
non-smoking asthmatics. These results suggest the implication of IL-18 in airway hyperrespon-
siveness characterizing bronchial asthma, which is modified by smoking.
ª 2009 Elsevier Ltd. All rights reserved.Background
Bronchial asthma is a complex disease characterized by
airway hyperresponsiveness (AHR) and reversible airflow
obstruction associated with airway inflammation and
remodeling.1e5 Active cigarette smoking has detrimental
effects on asthma morbidity. Compared with non-smokers
with asthma, smokers with asthma have more severe
symptoms,6 accelerated decline in lung function,7,8 and
impaired therapeutic responses to inhaled9,10 and oral
corticosteroids.11
IL-18 is a pleiotropic, pro-inflammatory cytokine
released from activated monocytes/macrophages and
airway epithelial cells, which is known to influence the
balance of Th1/Th2 immune response.12,13 The role of IL-18
in asthma is complex; IL-18 seems to produce antiallergic
reactions in the presence of Th1 cytokines, however,
injection of IL-18 alone also induces Th2 cytokines. IL-18 is
a cytokine with potent interferon (IFN)-g inducing activity
and can increase serum IgE levels and promote allergen-
induced eosinophil influx into the airways of mice in asthma
models.14,15
Cigarette smoking activates the inflammatory cells in
the airways and airway epithelial cells to release inflam-
matory peptides,16 and alters the immunophenotypic
profile of asthmatic patients by switching it towards
a Th1 pattern exerting immunomodulatory properties.16,17
Cigarette smoking induces epithelial apoptosis, stimulates
proteases and chemokines and activates a variety of cas-
pases via IL-18Ra dependent mechanisms.18e20 Recently,
we showed increased levels of IL-18 in induced sputum from
patients with COPD, which were associated with airflow
limitation, suggesting that IL-18 may be implicated in the
pathogenesis of cigarette induced COPD.21
To our knowledge, there are limited data on human
bronchial asthma concerning the association of IL-18 with
AHR. McKay et al.22 have shown reduced IL-18 levels in
induced sputum in both asthmatic and healthy smokers
compared to non-smokers which were associated with
a decrease in IL-18 mRNA expression in sputum cells; Tanaka
et al.23 have shown that IL-18 may play a potential role to
activate immunologic responses in mild and moderate
asthma exacerbation, and Kumano et al.24 have shown that
IL-18 may contribute to the development and exacerbation
of airway inflammation in asthma. Most of the information
reported as yet concerning the role of IL-18 in airway
inflammation and bronchial hyperreactivity in asthma are
mainly analyzed by in vitro and in vivo animal studies.
Based on the above data, we aimed to identify and
quantify IL-18 levels in sputum samples obtained from non-
smoking and smoking mild asthmatics, and furthermore, to
evaluate the associations between IL-18 levels in induced
sputum and airway hyperresponsiveness.Methods
Subjects
Forty six patients with stable asthma (24 smokers and
22 non-smokers), and thirty three healthy subjects
(16 smokers and 17 non-smokers) were included in the study.
Asthma was diagnosed with the American Thoracic Society
guidelines,25 mild asthma was defined according to GINA,26
and stable asthma was defined as no asthma exacerbation
within 6 months prior to study entry, and no respiratory
infection or antibiotic use within the preceding 6 weeks.
Smokers aged over 55 years old, and those with chronic
obstructive pulmonary disease (COPD) were excluded from
the study.
All healthy smokers were lifelong smokers (10 pack
years), with no history of lung disease, no chronic respira-
tory symptoms, and normal spirometry. Healthy non-
smokers were asymptomatic and had no history of asthma
or other respiratory disease, or any allergic condition.
Subjects were taking only inhaled short-acting b2 agonists
on an as needed basis for their asthma. Atopic status was
measuredbyskin-prick testingusing13commonaeroallergens
applied to the forearm.Theallergens tested (HALallergenLab
B. V. Harlem) were house dust mites (Dermatophagoides
pteronyssinus and Dermatophagoides farinae), household
pets (cat and dog), pollens (mixed grass, olive, mixed weed,
and Parietaria judaica) andmolds (alternaria, andAspergillus
fumigatus). Histamine and glycerinated saline solution were
used as positive and negative controls. A skin-prick test result
was considered positive if the mean wheal diameter was at
least 3 mm.
At the time of the study all subjects were in a stable
clinical condition as demonstrated by the low daily variability
(<15%) of peak flow measurements during the two weeks
before the study and by the low variability in forced expira-
tory volume in one second (FEV1) performed in the two days
of the study. All subjects had lung function within the normal
range and methacholine airway responsiveness with the dose
required to provoke a fall in FEV1 of 20% ormore (PD20FEV1) of
<1600 mg. Each subject attended the laboratory once two
separate visits within one week. On visit one, sputum
induction was performed after reversibility test. On visit two,
patients underwent methacholine provocation challenge and
skin-prick tests.
All subjects gave informed consent for participation in the
study, which was approved by the Hospital ethics committee.
Pulmonary function and bronchial
hyperreactivity tests
Pulmonary function (FEV1, FEV1/FVC) was measured with
a dry wedge spirometer (Masterscreen, Jaeger, Hoechberg,
IL-18 and AHR in bronchial asthma, effect of smoking 1921Germany) according to standardized guidelines,27 by the
same technician using the same spirometer. Reversibility
test was performed 20 min after inhalation of 200 mg sal-
butamol via a metered dose inhaler. Subjects were not
allowed to use short-acting bronchodilators within 12 h, or
long-acting bronchodilators within 24 h.
Methacholine chloride (Sigma Chemical; St. Louis, MO)
were dissolved in normal saline solution to produce
doubling concentrations range of 0.39e200 mg/ml for
methacholine and immediately used for bronchial chal-
lenge (Masterscreen, Jaeger, Hoechberg, Germany). The
first nebulization administered in each challenge was
normal saline solution, and the post-saline solution FEV1
was used as the baseline for the calculation of subsequent
percentage fall in FEV1. After challenge with saline solu-
tion, doubling concentrations of methacholine chloride
were inhaled. Because of the effect of a deep inspiration on
subsequent airway tone only one measurement for FEV1
was performed 60e90 s after inhalation of each concen-
tration unless the forced expiratory maneuver was judged
technically unsatisfactory.
The test was interrupted when a 20% decrease in FEV1
from the post-saline solution value was recorded or when
the highest concentration was reached. A log dosee
response curve was constructed for each challenge, and the
provocative dose of methacholine that caused a 20% fall in
FEV1 (PD20) was calculated by logarithmic interpolation.
Sputum induction and processing
Sputum was induced by inhalation of hypertonic saline
aerosol and processed as described previously.28 Briefly,
15 min after salbutamol inhalation (200 mg), normal saline
0.9% and then hypertonic saline (3%, 4% and 5%) nebulized
by an ultrasonic nebulizer (ULTRA-NEB 2000, DeVilbiss
Heathcare INC, Somerset, USA) was inhaled for each
concentration over a period of 7 min. Subjects were
encouraged to cough deeply after the 7-min intervals. All
subjects produced an adequate aliquot of sputum which
was processed within 2 h after termination of the induc-
tion. Sputum samples were transferred to a Petri dish and
the volume and macroscopic characteristics of the whole
sample recorded. Sputum plugs were separated from
contaminating saliva using sterile forceps. The plugs were
placed in a pre-weighed tube and the weight recorded. The
sputum then diluted threefold with phosphate bufferTable 1 Subjects’ characteristics.
Healthy non-smokers
nZ 17
Healthy sm
nZ 16
Age (years) 42 14 43 6
Smoking (pack years) 0 29 9
FEV1 (% pred) 105 12 103 9
FVC (% pred) 106 9 108 11
FEV1/FVC 83 6 80 4
Atopy () 7/17 7/19
Mch ()
PD20 (mg) 950 963
Values are expressed as mean SE.solution containing freshly prepared dithiothreitol (final
concentration: 1 mmol/l) (Sigma Chemical Co, Poole, UK).
The sample was vortexed briefly and incubated at 37 C for
15 min with constant agitation. The suspension was filtered
through monofilament filter cloth to remove mucus, then
centrifuged at 790 g for 4 min (4 C), and the pellet was
resuspended. Total cell counts were determined with
a Neubauer haemocytometer (VWR International Ltd,
Poole, UK) using tryptan blue exclusion to determine cell
viability; dead cells and epithelial cells were excluded.
Cell smear preparations were made using cytocentrifuge
at 500 g for 2 min (Cytospin 3, Shandon, INC, Pittsburgh,
USA). Sputum cytospin slides were stained with Maye
Gru¨nwaldeGiemsa for differential cell counts. Counting of
400 non-squamous cells took place in a blinded way by one
technician. Sputum samples containing >20% of squamous
cells and with cell viability <70% were excluded from
analysis as indication of poor cytospin quality. The super-
natant was stored at 80 C for subsequent assay for IL-18,
concentrations, which were measured using an enzyme-
linked immunosorbent assay kit (ELISA) (R & D Systems,
Minneapolis, Minnesota, USA). The sensitivity of the assay
used was 12.5 pg/ml.
Statistical analysis
Data were expressed in mean (SD) or median values. IL-18
was expressed in median values and inter-quartile range.
PD20 data were log transformed and reported as geometric
means. Differences between subjects’ groups were initially
assessed by KruskaleWallis test, and if significant, the
ManneWhitney rank test was then assessed. Correlations
between inflammatory cells and IL-18 levels in sputum,
smoking characteristics or lung function parameters were
calculated with Spearman’s rank correlation test. Statis-
tical analysis was not influenced by values at the lower
limits of detection since the non-parametric tests used
were based on ranks of values.
A p-value of less than 0.05 was considered significant.
Results
All smokers were matched for age and smoking pack years.
The clinical characteristics of the subjects participated in
the study are shown in Table 1.okers Non-smoking asthmatics
nZ 22
Smoking asthmatics
nZ 24
44 11 46 7
0 31 15
98 17 94 15
105 16 101 14
77 8 76 10
13/7 10/13
14/8 13/11
241 233
Figure 1 Levels of IL-18 (pg/ml), expressed as median values
(inter-quartile range) in induced sputum of healthy subjects
(non-smokers and smokers) and asthma patients (non-smokers
and smokers). *p< 0.05.
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The median (inter-quartile range) total number of cells was
significantly higher (p< 0.05) in smoking asthmatics
compared to healthy non-smokers (p< 0.05) (Table 2).
Smokers with asthma had significantly higher percentage of
sputum neutrophils, and significantly lower percentages of
sputum macrophages and eosinophils compared to non-
smoking asthmatics (p< 0.05). Finally, patients with
asthma (smokers and non-smokers) had significantly higher
percentage of eosinophils compared to healthy smokers and
non-smokers (p< 0.05).
IL-18 levels in induced sputum
IL-18 levels were significantly higher in the induced sputum
of healthy non-smokers compared to healthy smokers
(pZ 0.048) (Fig. 1). In the induced sputum samples of
asthma non-smokers IL-18 levels were significantly higher
compared to those of asthma smokers (pZ 0.037) (Fig. 1).
IL-18 levels in sputum were not significantly different
between healthy and asthmatic smokers, as well as,
between healthy and asthmatic non-smokers (p> 0.05).
IL-18 levels in induced sputum inversely correlated with
FEV1 (% pred) (rZ0.495, pZ 0.043) and PD20meth
(rZ0.621, pZ 0.024) in non-smoking asthmatics (Figs.
2(a) and 3). In contrast, in smoking asthmatics, IL-18 levels
in induced sputum were positively correlated with FEV1
(% pred) (rZ 0.627, pZ 0.002), FVC (% pred) (rZ 0.460,
pZ 0.031), FEV1/FVC (rZ 0.416, pZ 0.05), and PD20meth
(rZ 0.809, pZ 0.005) (Figs. 2(bed) and 3).
No correlation was found between IL-18 levels, pack
years, any specific cell type, and atopy.
Discussion
In this study, it was demonstrated that IL-18 levels are
decreased in the induced sputum samples obtained from
healthy and asthmatic smokers compared to non-smoking
subjects, respectively. Furthermore, it was shown that IL-
18 levels in sputum were correlated with airflow limitation
and AHR in an inverse way in smoking and non-smoking
asthmatics, suggesting that cigarette smoking modifies the
association between IL-18, pulmonary function and airway
hyperresponsiveness in patients with asthma. This is the
first study, at least to the authors’ knowledge, to show the
correlation of IL-18 levels in sputum, obtained fromTable 2 Total and differential cell counts in sputum.
Healthy non-smokers
nZ 17
Healthy sm
nZ 16
Total no of cells, 104 43 (8e230) 56 (30e15
Macrophages, % 56 (14e86) 48 (39e67
Neutrophils, % 30 (12e59) 39 (19e59
Eosinophils, % 0.75 (0.3e1.35) 0.7 (0.1e2.
Values are expressed as median (inter-quartile range).
*p< 0.05 versus healthy non-smokers; {p< 0.05 versus healthy smokeasthmatic patients in stable state, with airflow limitation
and AHR, and to examine the effect of cigarette smoking.
The finding of decreased IL-18 levels in the sputum of
smoking subjects is not surprising since McKay et al.22 had
previously showed reduced IL-18 levels in induced sputum
in both asthmatic and healthy smokers compared to non-
smokers, which were associated with a decrease in IL-18
mRNA expression in sputum cells. Cigarette smoking
promotes neutrophil influx into the airways16 and increases
protease activity.29 This may contribute to the degradation
of sputum IL-18 in smokers, especially in asthmatics, and
may partly explain the decreased levels of IL-18 in smokers.
Another explanation for the reduced levels of IL-18 in
smokers could be attributed to the fact that cigarette
smoking suppresses the ability of alveolar macrophages to
secrete pro-inflammatory cytokines such as TNF-a in
response to inflammatory stimuli.30 Furthermore, smoking
has also been shown to reduce the number of cells spon-
taneously secreting Th1 cytokines in the airways.31 Inter-
estingly, in COPD patients IL-18 levels in the induced
sputum were found significantly higher compared to
healthy smokers and non-smokers,21 probably, according to
the authors, due to the bacterial colonization of the
bronchial tree in COPD patients, which inducesokers Non-smoking asthmatics
nZ 22
Smoking asthmatics
nZ 24
9) 66 (4e282) 75 (16e320)*
9) 63 (17e93) 49 (5e95)#
) 29 (0.5e56) 49 (4e78)#
2) 8 (0.4e38)*{ 4 (0.8e21)*#{
rs; #p< 0.05 versus non-smoking asthmatics.
Figure 2 Spearman’s rank correlation: IL-18 levels and lung function in non-smoking (a) and smoking asthmatics (b, c, d).
IL-18 and AHR in bronchial asthma, effect of smoking 1923immunomodulatory effects on airway epithelia, posing the
distinct role IL-18 may play in COPD as compared to
asthma.22
In the present study, higher number of inflammatory
cells and percentage of neutrophils were demonstrated in
the induced sputum of asthma smokers compared to
healthy smokers, and non-smoking asthmatics. It is well
established, that cigarette smoking has an impact on
asthmatic airway inflammation, with evidence of an
increase in sputum cell count, relative and absolute neu-
trophilia, and increased levels of the potent neutrophilFigure 3 Spearman’s rank correlation: IL-18 levels anchemoattractant IL-8 in smoking, compared to non-smoking
asthmatics.16 Nevertheless, in patients with stable asthma
chronic inflammation is not only characterized by eosino-
phils, mast cells and allergen specific T cells, but also by
neutrophils.32,33 Although, no relationship was found
between IL-18 levels and neutrophil counts, several studies
underline the role of neutrophils in activating IL-18. Hay-
ashi et al.34 reported that ovalbumin (OVA) and IL-18
nasally administered act on memory type T helper (Th)1
cells to induce airway hyperresponsiveness (AHR) and
inflammation, and they suggested that IL-18 might relate tod PD20meth in smoking and non-smoking asthmatics.
1924 N. Rovina et al.chronic airway inflammation through neutrophils in smoker
asthmatics. Neutrophil proteinases, such as neutrophil
proteinase-3,35 can also be involved in the production of
active IL-18.
In our study, increased levels of IL-18 in induced sputum
of mild, non-smoking asthmatics in stable state were
associated with airflow limitation and airway hyper-
responsiveness (AHR). A significant correlation between
IL-18 serum levels and the disease severity of bronchial
asthma has been previously reported,23 with serum IL-18
levels to have a tendency to correlate inversely with PEF in
acute asthma and decrease quickly after asthma therapy,
suggesting that serum IL-18 values may partly reflect
disease activity in mild and moderate asthma. There are no
studies assessing IL-18 levels in induced sputum in different
severity levels of asthma. It could be speculated that IL-18
levels may be higher in more severe cases of asthma or in
refractory asthma but more studies are needed in order this
question to be addressed. As for AHR, there are no data on
the relationship in human bronchial asthma between IL-18
levels in sputum and bronchial hyperresponsiveness. There
are several studies however, exploring the role of IL-18 in
regulating airway inflammation and inducing AHR in murine
asthma models, which are revealing the complex roles of
IL-18 in these procedures.14,15,34,36,37 IL-18 is a cytokine
with potent interferon (IFN)-g inducing activity and can
increase serum IgE levels and promote allergen-induced
eosinophil influx into the airways of mice in asthma
models.14,15 In the study of Sugimoto et al.36 it was shown
that Ag and IL-18 stimulate memory Th1 cells to induce
severe airway inflammation and AHR in naı¨ve host mice.
Moreover, Hayashi et al.34 demonstrated that coadminis-
tration of OVA and LPS into Th1 mice induced AHR and
airway inflammation via endogenous IL-18. Finally, in a very
recent study37 it was shown that IL-18 may enhance chronic
airway inflammation and airway remodeling through the
production of IFN-g, IL-13 and TGF-b1 in the OVA-induced
asthma mouse model. In our study, the analysis conducted
between atopic and non-atopic asthmatics revealed no
differences in IL-18 levels in induced sputum, or in the
correlation of IL-18 levels with PD20 (data not shown). This
could be reasoned by the fact that chronic inflammation in
asthma is not only characterized by eosinophils, mast cells
and allergen specific T cells, and IL-18 is a cytokine highly
dependent on the surrounding airways’ milieu with complex
interactions with mediators and other cytokines that may
affect at each case its expression in the airways.
Interestingly, in smoking asthmatics, the association of
IL-18 levels in induced sputum was opposite to that
observed in non-smoking asthmatics. A positive correlation
was found between IL-18 levels and pulmonary function
parameters, whereas increased levels of IL-18 were asso-
ciated with lower AHR. Since smoking milieu affects
measurements of IL-18, it might also explain the different
relationship between FEV1 and IL-18 levels when comparing
smokers versus non-smokers. Cigarette smoke has a well-
known ability to modulate innate immunity and conse-
quently AHR, either by increasing the number of innate
immune effectors such as neutrophils and macrophages in
the lung or by regulating macrophage function and the
expression of genes involved in innate immune
responses.38,39 A possible explanation for the ‘‘protective’’effect of IL-18 on AHR in smoking asthmatics could be
attributed to the nature of IL-18 per se. IL-18 is a cytokine
highly dependent on proteolytic processing for its activity
and extracellular secretion. It is produced initially as an
inactive precursor, pro-IL-18, which is cleaved by caspase-
1 into active protein.40 Other proteases, however, such as
caspase-3,41 can cleave active IL-18 into inactive frag-
ments. Furthermore, smoking has also been shown to
reduce the number of cells spontaneously secreting Th1
cytokines in the airways.31
In conclusion, in this study it was demonstrated that
IL-18 levels are decreased in induced sputum of smoking
healthy subjects and smoking asthmatics, and that are
closely correlated with airflow limitation and airway
hyperresponsiveness (AHR) in non-smoking asthmatics.
Furthermore, it was shown that cigarette smoke modifies
the association of IL-18 with airflow limitation and AHR in
asthma patients. Like many patient-based clinical studies,
this is an observational study, which cannot establish the
role of IL-18 in the procedures inducing AHR in bronchial
asthma. It demonstrates though, the clinical relevance of
the findings of previously conducted animal studies in
humans, further supporting the implication of IL-18 in the
pathogenesis of asthma.
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